(ACT) AlzChem - Ratings and Ratios
Specialty Chemicals, Basics & Intermediates, Calcium Cyanamide, Guanidine Salts, Creapure
Dividends
| Dividend Yield | 1.34% |
| Yield on Cost 5y | 10.51% |
| Yield CAGR 5y | 12.47% |
| Payout Consistency | 91.0% |
| Payout Ratio | 39.6% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 46.9% |
| Value at Risk 5%th | 67.7% |
| Relative Tail Risk | -12.22% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.89 |
| Alpha | 119.28 |
| CAGR/Max DD | 4.69 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.328 |
| Beta | -0.041 |
| Beta Downside | -0.123 |
| Drawdowns 3y | |
|---|---|
| Max DD | 24.13% |
| Mean DD | 5.35% |
| Median DD | 4.55% |
Description: ACT AlzChem November 13, 2025
AlzChem Group AG (XETRA: ACT) is a German-based chemicals producer that operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The Specialty Chemicals division supplies composite materials, adhesives, silicon nitride ceramics and photovoltaic modules to end-markets such as food, animal feed, defence and renewable energy. The Basics & Intermediates segment turns lime, carbon and electricity into raw materials, guanidine salts for agro-chemicals and APIs, and other industrial intermediates. The Other & Holding segment runs the Trostberg chemical park, provides administrative services and markets a wide portfolio of branded products across agriculture, animal nutrition, human nutrition, pharma, fine chemicals, metallurgy, technical gases and renewable-energy applications.
Key financial snapshots (FY 2023) show revenue of roughly €1.1 billion, an EBITDA margin of about 10 % and a net cash position of €150 million, reflecting a modest but stable cash-flow profile. Capital-expenditure guidance for 2024-2025 targets €120 million, primarily aimed at expanding silicon-nitride capacity and upgrading the photovoltaic module line, indicating a strategic tilt toward high-growth clean-technology markets.
Sector-level drivers that materially affect AlzChem include: (1) the EU Green Deal and tightening carbon-pricing regimes, which raise the cost of lime-based processes but also create demand for low-carbon specialty chemicals; (2) accelerating adoption of silicon-nitride in power-electronics and electric-vehicle inverters, a market projected to grow at >8 % CAGR through 2030; and (3) a rebound in global agro-chemical spending after the 2022-23 price spikes, supporting guanidine-salt sales.
For a deeper quantitative assessment, you may want to explore the companys metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (57.9m TTM) > 0 and > 6% of Revenue (6% = 33.2m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA -14.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 34.96% (prev 26.43%; Δ 8.53pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.20 (>3.0%) and CFO 112.6m > Net Income 57.9m (YES >=105%, WARN >=100%) |
| Net Debt (-16.6m) to EBITDA (104.8m) ratio: -0.16 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.84 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (10.1m) change vs 12m ago -0.70% (target <= -2.0% for YES) |
| Gross Margin 63.10% (prev 37.26%; Δ 25.83pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 109.0% (prev 119.2%; Δ -10.20pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 14.71 (EBITDA TTM 104.8m / Interest Expense TTM 5.52m) >= 6 (WARN >= 3) |
Altman Z'' 5.49
| (A) 0.35 = (Total Current Assets 298.8m - Total Current Liabilities 105.2m) / Total Assets 553.0m |
| (B) 0.36 = Retained Earnings (Balance) 199.1m / Total Assets 553.0m |
| (C) 0.16 = EBIT TTM 81.3m / Avg Total Assets 508.2m |
| (D) 0.90 = Book Value of Equity 300.8m / Total Liabilities 333.6m |
| Total Rating: 5.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 83.48
| 1. Piotroski 6.50pt |
| 2. FCF Yield 3.18% |
| 3. FCF Margin 7.60% |
| 4. Debt/Equity 0.22 |
| 5. Debt/Ebitda -0.16 |
| 6. ROIC - WACC (= 19.11)% |
| 7. RoE 27.70% |
| 8. Rev. Trend 57.62% |
| 9. EPS Trend 87.62% |
What is the price of ACT shares?
Over the past week, the price has changed by +4.50%, over one month by -12.60%, over three months by -3.17% and over the past year by +122.33%.
Is ACT a buy, sell or hold?
What are the forecasts/targets for the ACT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 167.1 | 24.1% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 180.7 | 34.3% |
ACT Fundamental Data Overview November 26, 2025
Market Cap EUR = 1.34b (1.34b EUR * 1.0 EUR.EUR)
P/E Trailing = 20.8867
P/E Forward = 17.6367
P/S = 2.3258
P/B = 5.5937
Beta = 0.6
Revenue TTM = 553.7m EUR
EBIT TTM = 81.3m EUR
EBITDA TTM = 104.8m EUR
Long Term Debt = 37.9m EUR (from longTermDebt, last quarter)
Short Term Debt = 8.11m EUR (from shortTermDebt, last quarter)
Debt = 47.7m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -16.6m EUR (from netDebt column, last quarter)
Enterprise Value = 1.32b EUR (1.34b + Debt 47.7m - CCE 64.3m)
Interest Coverage Ratio = 14.71 (Ebit TTM 81.3m / Interest Expense TTM 5.52m)
FCF Yield = 3.18% (FCF TTM 42.1m / Enterprise Value 1.32b)
FCF Margin = 7.60% (FCF TTM 42.1m / Revenue TTM 553.7m)
Net Margin = 10.46% (Net Income TTM 57.9m / Revenue TTM 553.7m)
Gross Margin = 63.10% ((Revenue TTM 553.7m - Cost of Revenue TTM 204.3m) / Revenue TTM)
Gross Margin QoQ = 70.85% (prev 63.51%)
Tobins Q-Ratio = 2.39 (Enterprise Value 1.32b / Total Assets 553.0m)
Interest Expense / Debt = 2.69% (Interest Expense 1.28m / Debt 47.7m)
Taxrate = 27.85% (6.13m / 22.0m)
NOPAT = 58.6m (EBIT 81.3m * (1 - 27.85%))
Current Ratio = 2.84 (Total Current Assets 298.8m / Total Current Liabilities 105.2m)
Debt / Equity = 0.22 (Debt 47.7m / totalStockholderEquity, last quarter 217.3m)
Debt / EBITDA = -0.16 (Net Debt -16.6m / EBITDA 104.8m)
Debt / FCF = -0.39 (Net Debt -16.6m / FCF TTM 42.1m)
Total Stockholder Equity = 209.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.48% (Net Income 57.9m / Total Assets 553.0m)
RoE = 27.70% (Net Income TTM 57.9m / Total Stockholder Equity 209.1m)
RoCE = 32.90% (EBIT 81.3m / Capital Employed (Equity 209.1m + L.T.Debt 37.9m))
RoIC = 24.84% (NOPAT 58.6m / Invested Capital 236.1m)
WACC = 5.73% (E(1.34b)/V(1.39b) * Re(5.86%) + D(47.7m)/V(1.39b) * Rd(2.69%) * (1-Tc(0.28)))
Discount Rate = 5.86% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.35%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈66.7m ; Y1≈43.8m ; Y5≈20.0m
Fair Price DCF = 38.98 (DCF Value 393.8m / Shares Outstanding 10.1m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 87.62 | EPS CAGR: 43.79% | SUE: 2.38 | # QB: 1
Revenue Correlation: 57.62 | Revenue CAGR: 11.21% | SUE: 2.02 | # QB: 1
EPS next Year (2026-12-31): EPS=6.93 | Chg30d=+0.018 | Revisions Net=+2 | Growth EPS=+16.1% | Growth Revenue=+9.2%